GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Fatty Liver Disease/Ketogenic Diets in MASLD: Journal of Hepatology | March 2026
47

Ketogenic Diets in MASLD: Journal of Hepatology | March 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated March 1, 2026

Introduction

Ketogenic diets, characterized by very low carbohydrate intake and increased fat consumption, have gained significant attention as a potential therapeutic strategy in metabolic dysfunction-associated steatotic liver disease. The rationale is biologically appealing: by reducing insulin levels and promoting lipolysis and hepatic β-oxidation, ketogenic diets may rapidly decrease intrahepatic fat and improve metabolic parameters. In an era where lifestyle interventions remain the cornerstone of MASLD management, understanding whether dietary composition—beyond simple caloric restriction—can meaningfully influence liver fat is of major clinical importance.

Summary

This article critically evaluates a recent mechanistic study suggesting superior reductions in intrahepatic triglyceride content and insulin resistance with ketogenic diets compared to non-ketogenic diets. While the findings support a “starvation-like” metabolic shift with increased fat oxidation and reduced insulin levels, the authors highlight key methodological limitations that challenge causal interpretation. The most important concern is the non-randomized crossover design, where all participants received the ketogenic diet first, followed by the non-ketogenic diet after a prolonged interval, introducing significant time-related confounding. Additionally, a substantial imbalance in protein intake between the two diets raises the possibility that observed metabolic changes may be driven by increased protein rather than ketosis itself. Finally, reliance on HOMA-IR as a surrogate for hepatic insulin sensitivity is questioned, as reductions in insulin and glucose during low-carbohydrate intake may reflect decreased metabolic demand rather than true improvement in insulin signaling. Overall, while ketogenic diets show potential in reducing liver fat, these findings underscore the need for rigorously designed trials before attributing benefits specifically to carbohydrate restriction.

Related Q&A

48

GLP-1 RA in Gastroenterology: Digestive and Liver Disease | March 2026

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now widely used for type 2 diabetes and obesity, two conditions frequently encountered in gastroenterology practice. Their effects extend far beyond...

49

Resmetirom and MASLD Spectrum: Hepatology Communi — March 2026

Introduction Metabolically associated steatotic liver disease (MASLD) has become one of the most common causes of chronic liver disease worldwide, closely linked to the global epidemics of obesity...

50

Conventional Cardiovascular Risk Scores Underperform in Patients With MASLD: AMJ, March 2026

Metabolically–dysfunction–associated steatotic liver disease (MASLD) is strongly linked to cardiometabolic disorders, and cardiovascular disease (CVD) remains the leading cause of mortality in these patients. However, it is unclear...

51

Lean MASLD: Why Exercise Matters More Than Weight Loss: Gastroenterology | March 2026

Introduction – MASLD in Normal-Weight Individuals Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD...

52

Dapagliflozin Reduces Liver Fat Independent of Weight Loss in T2D Obesity | Feb 2026 | DOI: 10.1002/oby.70134

Introduction In type 2 diabetes, hepatic steatosis is common and contributes to cardiometabolic risk. SGLT2 inhibitors improve weight and glycemia, but whether they reduce liver fat through weight...

53

Do Patients Want MASLD Screening? Hepatology | February 2026

Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer